Compositions and method for treating affective, painful or allergic disorders
AssigneeGideon Pharmaceuticals, Inc.
InventorJoel E. Bernstein
Life of this patent
Estimating the term…
Abstract
Therapeutic compositions of doxepin and having a preponderance of the cis doxepin isomer over the trans doxepin isomer provide therapeutic effects for affective, painful, or allergic disorders without the sedative effects commonly experienced with compositions having a preponderance of the trans doxepin isomer.
Claims14
Claims:
- A composition comprising a preponderance of cis doxepin isomer over trans doxepin isomer, said cis doxepin isomer being present in an amount of about 0.01% to about 10.0% by weight, and a pharmaceutically acceptable vehicle, said composition for use in the treatment of affective, painful, allergic disorders, said composition being comparable in efficacy to compositions containing a preponderance of the trans doxepin isomer but with significantly less sedative effects.
A method of treating affective, painful or allergic disorders comprising treatment with an effective amount of a composition containing a preponderance of cis doxepin isomer over trans doxepin isomer, said cis doxepin isomer being present in an amount of about 0.01% to about 10.0% by weight in a pharmaceutically acceptable vehicle, said composition being comparable in efficacy to compositions containing a preponderance of the trans doxepin isomer but with significantly less sedation.
A composition suitable for oral administration comprising a pharmaceutically acceptable vehicle in the form of capsules, tablets, liquid solutions or suspensions and containing a preponderance of cis doxepin isomer over trans doxepin isomer, said cis doxepin isomer present in an amount of about 0.5-500.0 mg per capsule, tablet or 5 ml portion of liquid, said composition being comparable in efficacy to compositions containing a preponderance of the trans doxepin isomer but with significantly less sedative side effects.
A method of treating affective, painful, or allergic disorders by oral administration and comprising treatment with an effective amount of a composition containing a preponderance of cis doxepin isomer over trans doxepin isomer, said cis doxepin isomer being present in an amount of about 0.5-500.0 mg per dose or 5 ml portion of liquid in a pharmaceutically acceptable vehicle, said composition being comparable in efficacy to compositions containing a preponderance of trans doxepin isomer but with significantly less sedative side effects.
Dependencies are inferred from the claim text.